Exagen outlines $65M-$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline
Source: SeekingAlpha
2025-07-29 15:10:18 ET
More on Exagen
- Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
- Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
- Exagen GAAP EPS of -$0.21 misses by $0.06, revenue of $17.2M beats by $0.89M
- Exagen prices public offering of common stock
- Seeking Alpha’s Quant Rating on Exagen
Read the full article on Seeking Alpha
For further details see:
Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline
Exagen Inc.
NASDAQ: XGN
XGN Trading
3.08% G/L:
$3.4015 Last:
603,728 Volume:
$3.40 Open:
XGN Latest News
February 24, 2026 09:00:00 am
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
XGN Stock Data
$80,000,739
13,869,817
3.15%
15
N/A
Medical Diagnostics & Screening
Healthcare
US
Vista
